BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 23453789)

  • 1. Resolute zotarolimus-eluting stent to treat bifurcated lesions according to the provisional technique: a procedural performance comparison with sirolimus- and everolimus-eluting stents.
    Burzotta F; Trani C; Talarico GP; Tommasino A; Todaro D; Coluccia V; Pirozzolo G; Niccoli G; Leone AM; Porto I; Schiavoni G; Crea F
    Cardiovasc Revasc Med; 2013; 14(3):122-7. PubMed ID: 23453789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach.
    Burzotta F; Trani C; Todaro D; Mariani L; Talarico GP; Tommasino A; Giammarinaro M; Niccoli G; Porto I; Leone AM; Mongiardo R; Mazzari MA; Schiavoni G; Crea F
    JACC Cardiovasc Interv; 2011 Mar; 4(3):327-35. PubMed ID: 21435612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bifurcation treatment with novel, highly flexible drug-eluting coronary stents in all-comers: 2-year outcome in patients of the DUTCH PEERS trial.
    van der Heijden LC; Kok MM; Lam MK; Danse PW; Schramm AR; Jessurun GA; Tjon Joe Gin RM; van Houwelingen KG; Hautvast RW; Linssen GC; Sen H; Löwik MM; IJzerman MJ; Doggen CJ; von Birgelen C
    Clin Res Cardiol; 2016 Mar; 105(3):206-15. PubMed ID: 26329584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting.
    Pan M; Medina A; Suárez de Lezo J; Romero M; Segura J; Martín P; Suárez de Lezo J; Hernandez E; Mazuelos F; Ojeda S
    Catheter Cardiovasc Interv; 2012 Dec; 80(7):1165-70. PubMed ID: 22511299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-, everolimus-, and sirolimus-eluting stent implantation.
    Song HG; Kang SJ; Ahn JM; Kim WJ; Lee JY; Park DW; Lee SW; Kim YH; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2014 May; 83(6):873-8. PubMed ID: 22815193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of everolimus-eluting stents versus paclitaxel-eluting stents in a diabetic population.
    Laynez A; Sardi G; Hauville C; Barbash IM; Pakala R; Torguson R; Xue Z; Satler LF; Pichard AD; Waksman R
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):759-65. PubMed ID: 22488756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year outcomes after deployment of XIENCE V everolimus-eluting stents in patients undergoing percutaneous coronary intervention of bifurcation lesions: a report from the SPIRIT V single arm study.
    Džavík V; Kaul U; Guagliumi G; Chevalier B; Smits PC; Stuteville M; Li D; Sudhir K; Grube E
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E163-72. PubMed ID: 23225766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial.
    Tandjung K; Basalus MW; Sen H; Stoel MG; van Houwelingen KG; Louwerenburg JH; de Man FH; Linssen GC; Saïd SA; Kleijne MA; van der Palen J; von Birgelen C
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):396-405. PubMed ID: 23359390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology.
    Talarico GP; Burzotta F; Trani C; Tommasino A; Niccoli G; Porto I; Leone AM; Mongiardo R; Schiavoni G; Crea F
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):268-73. PubMed ID: 22639426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dedicated two-stent technique in complex bifurcation percutaneous coronary intervention with use of everolimus-eluting stents: the EES-bifurcation study.
    Kherada NI; Sartori S; Tomey MI; Mennuni MG; Meelu OA; Roy S; Mohanty BD; Baber U; Pyo R; Kovacic JC; Sweeny J; Moreno P; Krishnan P; Dangas GD; Mehran R; Sharma SK; Kini AS
    Int J Cardiol; 2014 Jun; 174(1):13-7. PubMed ID: 24731975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus-eluting stents and zotarolimus-eluting stents for percutaneous coronary interventions: two-year outcomes in New York State.
    Hannan EL; Zhong Y; Wu C; Walford G; Holmes DR; Jacobs AK; Stamato NJ; Venditti FJ; Sharma S; Fergus I; King SB
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1097-105. PubMed ID: 22707353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
    Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial intravascular ultrasound analysis of complex bifurcation coronary lesions treated with the Tryton Bifurcation Stent in conjunction with an everolimus-eluting stent: IUVANT (Intravascular Ultrasound Evaluation of Tryton Stent) study.
    Bartorelli AL; Trabattoni D; Almonacid A; Fabbiocchi F; Montorsi P; Galli S; Grancini L; Ravagnani P; Mintz GS; Kaplan AV; Popma JJ; Maehara A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):544-53. PubMed ID: 25115944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents.
    Ferenc M; Buettner HJ; Gick M; Comberg T; Rothe J; Khoury F; Valina C; Toma A; Kuebler P; Riede F; Neumann FJ
    Clin Res Cardiol; 2016 Mar; 105(3):230-8. PubMed ID: 26329585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, time course and predictors of early vs. late target lesion revascularisation after everolimus-eluting stent implantation: a SPIRIT V substudy.
    Niccoli G; Stuteville M; Sudhir K; Li D; Montone RA; Bolognese L; Grube E
    EuroIntervention; 2013 Jul; 9(3):353-9. PubMed ID: 23482242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.